Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Replimune Group, Inc.NASDAQ: REPL

Research & Development · Q3 FY2026 · quarter ended Dec 2025

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $53.14M rose 10.7% year over year, behind the +26.2% change in trailing-twelve-month research & development. Sequentially, it fell 8.2% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.7% toward the trailing-twelve-month pace of +26.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$53.14M-8.2% QoQ
Last fiscal yearMar 2025
$189.45M+8.3% YoY
LTMDec 2025
$223.39M+26.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.7%——
1 year+8.3%——
3-year CAGR+32.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
189.45M USD
Year-over-year change
+8.3%
4-year CAGR
+34.7%

Research & Development vs competitors

How REPL compares with its peers on the latest reported figures

  • REPL's LTM Dec 2025 research & development of $223.39M is the 4th highest of the 11 companies compared; the peer median is $131.51M.
  • Its year-over-year change of +26.2% is the 3rd highest of 10, against a peer median of -11.7%.
  • Over three fiscal years its annual growth of +32.9% compares with a peer median of -5.7%.
REPL Competitors Peer median
Research & Development for REPL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M +33.2%-5.7%138.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M -19.7%+0.6%63.8%
REPLReplimune Group, Inc.LTM Dec 2025$223.39M +26.2%+32.9%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M -11.7%-0.1%489780.6%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M +60.8%+33.1%590.6%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$69.1M -13.8%-14.9%194.4%
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
CGENCompugen Ltd.LTM Mar 2026$23.92M -1.0%-9.4%32.9%
Peer median (excluding REPL) $131.51M-11.7%-5.7%112.2%

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue4.14M4.58M000
Gross Profit(4.14M)(4.58M)000
Gross Margin—————
Research & Development57.49M80.65M126.53M174.96M189.45M
Selling, General & Admin21.13M36.26M000
Operating Expenses78.62M116.91M177.08M234.77M261.63M
Depreciation & Amortization4.14M4.58M2.45M5.08M5.93M
EBITDA(76.48M)(114.41M)(171.72M)(227.77M)(253.92M)
EBITDA Margin—————
Operating Income(82.76M)(121.48M)(177.08M)(234.77M)(261.63M)
Operating Margin—————
Interest Income916K390K10.01M23.36M21.12M
Interest Expense3.06M2.22M4.16M6.66M7.89M
Other Income / Expenses(915K)278K3.08M19.39M14.8M
Income Before Tax(83.68M)(121.21M)(174M)(215.39M)(246.83M)
Pre-Tax Margin—————
Income Tax Expense(2.81M)(3.17M)288K408K468K
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Net Margin—————
EPS (Basic)(1.75)(2.26)(2.99)(3.24)(3.07)
EPS (Diluted)(1.75)(2.26)(2.99)(3.24)(3.07)
Weighted Avg Shares46.25M52.21M58.21M66.57M80.56M
Weighted Avg Shares (Diluted)46.25M52.21M58.21M66.57M80.56M

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.